Literature DB >> 24453713

The evolving role of the multiple sclerosis nurse: an international perspective.

Therese Burke1, Sara Dishon1, Lynn McEwan1, Jennifer Smrtka1.   

Abstract

A greater understanding of the pathogenesis of multiple sclerosis (MS) and the need for treatments with increased efficacy, safety, and tolerability have led to the ongoing development of new treatments. The evolution of treatments for MS is expected to have a dramatic impact on the entire health-care team, especially MS nurses, who build strong collaborative partnerships with their patients. MS nurses help patients better understand their disease and treatment options, facilitate the initiation and management of treatment, and encourage adherence. With new oral therapies entering the market, the potential for increased efficacy, tolerability, adherence, and convenience for patients is evident. However, the resulting change in the treatment paradigm means that the skill set required of an MS nurse will inevitably expand. There will be a growing need for professional training and development to ensure that nurses are familiar with the wider range of treatments and their specific modes of action, dosing schedules, and benefit/risk profiles. In addition, the MS nurse's role will expand to include management of the complex monitoring needs specific to each therapy. This article explores how the role of the MS nurse is evolving with the development of new MS therapies, including novel oral therapies.

Entities:  

Year:  2011        PMID: 24453713      PMCID: PMC3882972          DOI: 10.7224/1537-2073-13.3.105

Source DB:  PubMed          Journal:  Int J MS Care        ISSN: 1537-2073


  32 in total

Review 1.  Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS.

Authors:  Helen L Tremlett; Joel Oger
Journal:  Neurology       Date:  2003-08-26       Impact factor: 9.910

2.  The return of natalizumab: weighing benefit against risk.

Authors:  Douglas Goodin
Journal:  Lancet Neurol       Date:  2006-05       Impact factor: 44.182

3.  A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.

Authors:  Ludwig Kappos; Ernst-Wilhelm Radue; Paul O'Connor; Chris Polman; Reinhard Hohlfeld; Peter Calabresi; Krzysztof Selmaj; Catherine Agoropoulou; Malgorzata Leyk; Lixin Zhang-Auberson; Pascale Burtin
Journal:  N Engl J Med       Date:  2010-01-20       Impact factor: 91.245

4.  Factors that influence adherence with disease-modifying therapy in MS.

Authors:  Katherine Treadaway; Gary Cutter; Amber Salter; Sharon Lynch; James Simsarian; John Corboy; Douglas Jeffery; Bruce Cohen; Ken Mankowski; Joseph Guarnaccia; Lawrence Schaeffer; Roy Kanter; David Brandes; Charles Kaufman; David Duncan; Ellen Marder; Arthur Allen; John Harney; Joanna Cooper; Douglas Woo; Olaf Stüve; Michael Racke; Elliot M Frohman
Journal:  J Neurol       Date:  2009-04-27       Impact factor: 4.849

Review 5.  A review of disease-modifying therapies for MS: maximizing adherence and minimizing adverse events.

Authors:  David W Brandes; Teri Callender; Ellen Lathi; Shirley O'Leary
Journal:  Curr Med Res Opin       Date:  2009-01       Impact factor: 2.580

6.  Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.

Authors:  G Comi; A Pulizzi; M Rovaris; O Abramsky; T Arbizu; A Boiko; R Gold; E Havrdova; S Komoly; Kw Selmaj; B Sharrack; M Filippi
Journal:  Lancet       Date:  2008-06-21       Impact factor: 79.321

Review 7.  Addressing the need for increased adherence to multiple sclerosis therapy: can delivery technology enhance patient motivation?

Authors:  Alessandra Lugaresi
Journal:  Expert Opin Drug Deliv       Date:  2009-09       Impact factor: 6.648

Review 8.  Emerging oral therapies for multiple sclerosis.

Authors:  B A Cohen; P Rieckmann
Journal:  Int J Clin Pract       Date:  2007-09-03       Impact factor: 2.503

9.  Multiple sclerosis.

Authors:  Alastair Compston; Alasdair Coles
Journal:  Lancet       Date:  2008-10-25       Impact factor: 79.321

Review 10.  Recognizing nonadherence in patients with multiple sclerosis and maintaining treatment adherence in the long term.

Authors:  Kathleen Costello; Patricia Kennedy; Jo Scanzillo
Journal:  Medscape J Med       Date:  2008-09-30
View more
  4 in total

1.  A Qualitative Study of Health Care Professionals' Views on Bowel Care in Multiple Sclerosis: Whose Job Is It Anyway?

Authors:  Sue Woodward; Maureen Coggrave; Lesley Dibley; Doreen McClurg; Christine Norton
Journal:  Int J MS Care       Date:  2021-06-15

2.  Autoinjector preference in multiple sclerosis and the role of nurses in treatment decisions: results from an international survey in Europe and the USA.

Authors:  Elisabetta Verdun di Cantogno; Mark Tomlinson; Laure Manuel; Kunal Thakur
Journal:  Pragmat Obs Res       Date:  2014-12-12

3.  Behavioral aspects of nurse practitioners associated with optimal multiple sclerosis care in Spain.

Authors:  Gustavo Saposnik; Beatriz Del Río; Guillermo Bueno-Gil; Ángel P Sempere; Alejandro Lendínez-Mesa; Alfredo Rodríguez-Antigüedad; María Terzaghi; Nicolás Medrano; Jorge Maurino
Journal:  PLoS One       Date:  2021-12-08       Impact factor: 3.240

4.  "I would stress less if I knew that the nurse is taking care of it": Multiple Sclerosis inpatients' and health care professionals' views of their nursing-experience and nursing consultation in rehabilitation-a qualitative study.

Authors:  Verena Witzig-Brändli; Cordula Lange; Sabine Gschwend; Myrta Kohler
Journal:  BMC Nurs       Date:  2022-08-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.